Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13
Venture Financing 14
Confluence Life Sciences Raises USD4.8 Million in Financing 14
Aclaris Therapeutics Raises USD40 Million in Series C Financing 15
Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17
Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18
Confluence Life Sciences Raises Funds Through Venture Financing 19
Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20
Aclaris Therapeutics Raises US$21 Million In Series A Financing 21
Confluence Life Sciences Raises US$4 Million In Series A Financing 23
Partnerships 24
Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24
Licensing Agreements 25
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25
Vixen Pharma Enters into Licensing Agreement with Columbia University 26
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27
Equity Offering 28
Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28
Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30
Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32
Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33
Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35
Aclaris Therapeutics Raises USD63.3 Million in IPO 36
Acquisition 38
Aclaris Therapeutics Acquires Confluence Life Sciences 38
Aclaris Therapeutics to Acquire Vixen Pharma 39
Aclaris Therapeutics Inc – Key Competitors 40
Aclaris Therapeutics Inc – Key Employees 41
Aclaris Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 03, 2018: Aclaris Therapeutics reports second quarter 2018 financial results and provides update on clinical and commercial developments 43
May 08, 2018: Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments 46
Mar 12, 2018: Aclaris Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 49
Nov 07, 2017: Aclaris Therapeutics Reports Third Quarter 2017 Financial Results 53
Aug 08, 2017: Aclaris Therapeutics Reports Second Quarter 2017 Financial Results 57
May 09, 2017: Aclaris Therapeutics Reports First Quarter 2017 Financial Results 59
Mar 15, 2017: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 61
Corporate Communications 63
Jun 15, 2018: Aclaris Therapeutics Appoints Dr. David Gordon As Chief Medical Officer 63
Apr 24, 2018: Aclaris Therapeutics Announces Names Bryan Reasons As Director And Chairman Of Audit Committee 64
Aug 09, 2017: Aclaris Announces Appointment of Andrew Schiff to Board of Directors 65
Jan 26, 2017: Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors 66
Product News 67
05/15/2018: Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting 67
04/24/2017: Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting 68
Product Approvals 69
Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 69
Clinical Trials 70
Dec 19, 2017: Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo 70
May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13
Confluence Life Sciences Raises USD4.8 Million in Financing 14
Aclaris Therapeutics Raises USD40 Million in Series C Financing 15
Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17
Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18
Confluence Life Sciences Raises Funds Through Venture Financing 19
Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20
Aclaris Therapeutics Raises US$21 Million In Series A Financing 21
Confluence Life Sciences Raises US$4 Million In Series A Financing 23
Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24
Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25
Vixen Pharma Enters into Licensing Agreement with Columbia University 26
Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27
Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28
Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30
Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32
Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33
Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35
Aclaris Therapeutics Raises USD63.3 Million in IPO 36
Aclaris Therapeutics Acquires Confluence Life Sciences 38
Aclaris Therapeutics to Acquire Vixen Pharma 39
Aclaris Therapeutics Inc, Key Competitors 40
Aclaris Therapeutics Inc, Key Employees 41
Aclaris Therapeutics Inc, Subsidiaries 42
List of Figures
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer